enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Donanemab - Wikipedia

   en.wikipedia.org/wiki/Donanemab

   Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.

3. Eli Lilly Alzheimer's drug approved by US FDA - AOL

   www.aol.com/news/us-fda-approves-lillys...

   The approval for donanemab, to be sold under the brand name Kisunla, followed the recommendations of the agency's outside experts, who unanimously backed its use in patients with early Alzheimer's ...

4. How a new FDA-approved drug can — and can’t — help people ...

   www.aol.com/fda-approved-drug-t-help-121600044.html

   It’s called donanemab, a drug from pharmaceutical giant Eli Lilly. If the FDA approves donanemab, it could come later this year. But that doesn’t guarantee that Medicare will cover it either.

5. In an unusual move, FDA postpones approval decision for Lilly ...

   www.aol.com/news/unusual-move-fda-postpones...

   The Food and Drug Administration has pushed back its approval decision deadline for Eli Lilly’s experimental Alzheimer’s drug donanemab. Lilly applied to the FDA for approval of the drug in ...

6. Eli Lilly's Potential Alzheimer’s Drug Clears a Big Hurdle

   www.aol.com/eli-lillys-potential-alzheimer-drug...

   In Lilly’s studies, the death rate from ARIA was about 2.3% in those receiving donanemab compared to 1.9% in the placebo group after three years. What the committee found

7. FDA approves donanemab, Eli Lilly’s treatment for early ...

   www.aol.com/fda-approves-donanemab-eli-lilly...

   Lilly told a committee of FDA advisers in June that late-stage clinical research data showed “highly meaningful results” for people who took donanemab, with about 35% lower risk of progression ...

8. US FDA staff raise no major concerns about Eli Lilly ... - AOL

   www.aol.com/news/us-fda-panel-vote-data...

   An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients ...

9. Eli Lilly's Alzheimer's drug approved in Japan - AOL

   www.aol.com/news/eli-lillys-alzheimers-drug...

   Lilly said Japan is the second major market in which the drug has received approval, after the United States where it is sold under the same brand name Kisunla. The Alzheimer's Association ...